It’s the dog days of summer in much of the United States, “stupid hot”, but it’s not too early to be planning ahead for the fall cancer conferences coming up.
If like us, you don’t like staying out by the airport when you attend a conference, it’s often necessary to book your accommodation early.
We will be at three meetings in the busy September – December period after everyone returns from their summer holidays:
2013 European Cancer Congress in Amsterdam (twitter: #ECC2013)
Abstracts for ECCO 2013 will be published online approximately two weeks before the meeting.
Over the last two years in Vienna and Stockholm we have seen companies present noteworthy clinical data that missed the early cut-off for the ASCO annual meeting. It’s truly become a global meeting. If you have plans to be in Amsterdam, we hope to see you there.
Molecular Targets and Cancer Therapeutics in Boston (twitter #Targets13)
The annual AACR-NCI-EORTC international conference on Molecular Targets and Cancer Therapeutics alternates between the United States and Europe, and this year it’s being held in Boston from October 19-23, 2013.
Boston is rapidly becoming the world’s leading location for early-stage oncology drug development, so we are expecting some outstanding science at this meeting that will have a major impact on cancer drug development.
If anyone doubts the potential of what a poster at this meeting can do, it’s worth remembering that the idea for Abraxane in pancreatic cancer came from a preclinical poster presented at the Molecular Targets meeting in 2009, when it was last in Boston.
Boston is one of our favorite cities and the Hynes Convention Center is a convenient location for what should be one of the best scientific meetings of the year. Here’s a link to the preliminary program.
2013 ASH annual meeting in New Orleans (twitter #ASH13)
The last of this year’s cancer conferences that we will be attending is the American Society of Hematology annual meeting that takes place in New Orleans from December 7-10, 2013.
There was a lot of data at ASCO this year in Chronic Lymphyocytic Leukemia (CLL). If you missed it, the video interview with Dr Susan O’Brien from MD Anderson Cancer Center is well worth watching.
We expect this year’s ASH annual meeting to be one of the best ever in light of the pipeline of new treatments in lymphoma, leukemia and multiple myeloma for which data is expected. Book your hotel rooms early in New Orleans – we already have – the city is small and we expect it will be a sell out meeting hotel-wise!